Prithviraj Bose, MD: Optimizing Ruxolitinib With Sotatercept for Myelofibrosis

Dr. Bose discusses updated results from a phase II trial of sotatercept alone and with ruxolitinib, the only FDA-approved therapy for myelofibrosis, which also worsens anemia in these patients.

SHARE